Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 10

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 10
---
 the record date vote:

| ● | “FOR”                     
 the Merger Proposal; and  |
| ● | “FOR”                     
 the Adjournment Proposal. |

For more information on each proposal and the MIRA Board’s recommendations, please see the section entitled “ Matters Being Submitted to a Vote of MIRA’s Stockholders.”

Q: How many votes are needed to approve each proposal?

A:Approval of the proposals requires the affirmative vote of a majority of the votes cast virtually or by proxy at the MIRA virtual special meeting.

Q: What risks should I consider in deciding whether to vote in favor of Proposal Nos. 1 and 2?

A: You should carefully review the section of the proxy statement titled “ Risk Factors,” which sets forth certain risks and uncertainties related to the Merger, risks and uncertainties to which the combined company’s business will be subject, and risks and uncertainties to which each of MIRA and SKNY, as an independent company, is subject.

Q: When do you expect the Merger to be consummated?

A:We anticipate that the Merger will be consummated during the third quarter of 2025, soon after the MIRA virtual special meeting to be held on , but we cannot predict the exact timing. For more information, please see the section titled “ The Merger Agreement—Conditions to the Merger.”

Q: What are the material U.S. federal income tax consequences of the Merger to U.S. Holders of SKNY shares?

A:MIRA and SKNY intend the Merger to qualify as a reorganization within the meaning of Section 368(a) of the Internal Revenue Code of 1986, as amended (the “Code”), as described in the section titled “ The Merger—Material U.S. Federal Income Tax Consequences of the Merger.”

The tax consequences to each SKNY stockholder will depend on that stockholder’s particular circumstances. Each SKNY stockholder should consult with his, her or its tax advisor for a full understanding of the tax consequences of the Merger to that stockholder.

Q: What do I need to do now?

A:MIRA and SKNY urge you to read this proxy statement carefully, including its annexes and information incorporated herein, and to consider how the Merger affects you.

If you are a holder of MIRA Common Stock as of the record date, please vote your shares as soon as possible so that your shares will be represented at the MIRA virtual special meeting. Please follow the instructions set forth